United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

crescent pharma ltd - itraconazole - oral capsule - 100mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

mawdsley-brooks & company ltd - itraconazole - oral capsule - 100mg

Singapore - English - HSA (Health Sciences Authority)

goldplus universal pte ltd - itraconazole - solution - itraconazole 10 mg/ml

Israel - English - Ministry of Health

rafa laboratories ltd - itraconazole - capsules - itraconazole 100 mg - itraconazole - itraconazole - blastomycosis (pulmonary and extrapulmonary). histoplasmosis. onchomycosis caused by dermatophytes and/or yeast. dermatomycoses. vulvovaginal candidosis. oral candidosis.

Ireland - English - HPRA (Health Products Regulatory Authority)

focus pharmaceuticals ltd - itraconazole - oral solution - 10 milligram(s)/millilitre - triazole derivatives; itraconazole

Ireland - English - HPRA (Health Products Regulatory Authority)

ltt pharma limited - itraconazole - capsule - 100 milligram - itraconazole

Ireland - English - HPRA (Health Products Regulatory Authority)

pco manufacturing ltd. - itraconazole - capsule, hard - 100 milligram(s) - triazole derivatives; itraconazole

Ireland - English - HPRA (Health Products Regulatory Authority)

imbat limited - itraconazole - capsule, hard - 100 milligram(s) - triazole derivatives; itraconazole

Singapore - English - HSA (Health Sciences Authority)

johnson & johnson international (singapore) pte ltd - itraconazole - solution - 10 mg/ml - itraconazole 10 mg/ml

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - itraconazole, quantity: 100 mg - capsule - excipient ingredients: hypromellose; macrogol 20000; sucrose; hydrolysed maize starch; titanium dioxide; purified water; gelatin; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - apo-itraconazole indicated for use in adults for the treatment of: ? superficial dermatomycoses not responding to topical treatment. ? fungal keratitis which has failed to respond to topical treatment or where the disease is either progressing rapidly or is immediately sight threatening. ? pityriasis versicolor not responding to any other treatment. ? vulvovaginal candidiasis not responding to topical treatment. ? oral candidiasis in immunocompromised patients. ? onychomycosis caused by dermatophytes. ? systemic mycoses: - systemic aspergillosis, histoplasmosis, sporotrichosis. - treatment and maintenance therapy in aids patients with disseminated or chronic pulmonary histoplasmosis infection. - treatment of oropharyngeal and/or oesophageal candidiasis when first line systemic antifungal therapy is inappropriate or has proven ineffective. - treatment of non-invasive candidiasis in non-neutropenic patients when first-line systemic antifungal therapy is inappropriate or has proven ineffective. this may be due to underlying pathology, insensitivity of the pathogen or drug toxicity.